Medivation Inc. (MDVN) Sr. Vice President and CFO Clarence Patrick Machado sells 20,000 Shares

Sr. Vice President and CFO of Medivation Inc. (MDVN, Financial) Clarence Patrick Machado sells 20,000 shares of MDVN on 11/11/2009 at an average price of $28.28 a share.

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. The Company had built a portfolio of innovative medical technologies and a team of employees and seasoned consultants with significant expertise in the identification, evaluation, acquisition, development and sale/partnering of small molecule therapeutics, biotechnology products and medical devices Medivation Inc. has a market cap of $938.2 million; its shares were traded at around $28.03 with and P/S ratio of 74.6.

Insiders' Positions with MDVN

  • Sell:: President and CEO David Hung sold 25,000 shares of MDVN stock on 09/10/2009 at the average price of 25.84, the price of the stock has increased by 8.48% since

  • Sell:: President and CEO David Hung sold 25,000 shares of MDVN stock on 07/01/2009 at the average price of 22.62, the price of the stock has increased by 23.92% since



Insiders' Positions with MDVN

  • Sell:: Sr. Vice President and CFO Clarence Patrick Machado sold 20,000 shares of MDVN stock on 09/10/2009 at the average price of 25.86, the price of the stock has increased by 8.39% since

  • Sell:: Sr. Vice President and CFO Clarence Patrick Machado sold 20,000 shares of MDVN stock on 07/01/2009 at the average price of 22.48, the price of the stock has increased by 24.69% since



Insiders' Positions with MDVN

  • Sell:: Director Gregory Bailey sold 10,000 shares of MDVN stock on 09/14/2009 at the average price of 25.99, the price of the stock has increased by 7.85% since

  • Sell:: Chief Medical Officer Lynn Seely sold 18,000 shares of MDVN stock on 09/10/2009 at the average price of 25.87, the price of the stock has increased by 8.35% since

  • Sell:: Chief Commercial Officer Rohan Palekar sold 12,000 shares of MDVN stock on 09/10/2009 at the average price of 25.9, the price of the stock has increased by 8.22% since

  • Sell:: Chief Medical Officer Lynn Seely sold 18,000 shares of MDVN stock on 07/01/2009 at the average price of 22.37, the price of the stock has increased by 25.3% since

  • Sell:: Chief Commercial Officer Rohan Palekar sold 12,000 shares of MDVN stock on 06/30/2009 at the average price of 22.21, the price of the stock has increased by 26.2% since